SOURCE: Protherics PLC

November 26, 2007 11:30 ET

Protherics PLC - Director/PDMR Shareholding

Cheshire, UK--(Marketwire - November 26, 2007) -

                        Protherics PLC

               Notification of Directors' Interests

London, UK; Brentwood, TN, US; 26 November 2007 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, announces that, on 23 November 2007, a conditional right to receive 157,980 ordinary shares in Protherics ("Ordinary Shares") was awarded to Saul Komisar, President of Protherics Inc., under the terms of the Protherics PLC Long Term Incentive Plan (the "LTIP"). The award vests on the third anniversary of the date of grant subject to the achievement of performance conditions.

Protherics PLC also announces the grant, on 23 November 2007, of the following options over Ordinary Shares in the Company under the terms of the LTIP:

Name                 Position                     Number of Options
Andrew Heath         Chief Executive Officer                325,581

Rolf Soderstrom      Finance Director                       204,651

James Christie       Operations Director                    176,744

The options are exercisable between the third and tenth anniversary of the date of grant at an exercise price of 2 pence per share, subject to the achievement of performance conditions.

Following the above grant, the Directors hold options or conditional awards over the following number of Ordinary Shares:

Andrew Heath                                4,245,142

Rolf Soderstrom                               627,727

James Christie                              1,564,754

Saul Komisar                                1,271,081

The current issued ordinary share capital of the Company is 339,696,822 shares.

For further information please contact:


Nick Staples, Director of Corporate Affairs         +44 (0) 7919  480510
Julie Vickers, Company Secretary                    +44 (0)1928 518010

Financial Dynamics - press enquiries

London: Ben Atwell, Lara Mott                       +44 (0) 20 7831 3113
New York: John Capodanno, Jonathan Birt             +1 212 850 5600

Or visit

                      This information is provided by RNS
            The company news service from the London Stock Exchange